Cargando…
A Novel Therapeutic Strategy for the Treatment of Glioma, Combining Chemical and Molecular Targeting of Hsp90α
Hsp90α's vital role in tumour survival and progression, together with its highly inducible expression profile in gliomas and its absence in normal tissue and cell lines validates it as a therapeutic target for glioma. Hsp90α was downregulated using the post-transcriptional RNAi strategy (sihsp9...
Autores principales: | Mehta, Adi, Shervington, Leroy, Munje, Chinmay, Shervington, Amal |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Molecular Diversity Preservation International (MDPI)
2011
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3763420/ https://www.ncbi.nlm.nih.gov/pubmed/24213135 http://dx.doi.org/10.3390/cancers3044228 |
Ejemplares similares
-
Can RNAi-mediated hsp90α knockdown in combination with 17-AAG be a therapy for glioma?()
por: Mehta, Adi, et al.
Publicado: (2013) -
Could the Anti-Chaperone VER155008 Replace Temozolomide for Glioma Treatment
por: Shervington, Leroy, et al.
Publicado: (2015) -
A novel series of phenolic temozolomide (TMZ) esters with 4 to 5-fold increased potency, compared to TMZ, against glioma cells irrespective of MGMT expression
por: Shervington, Leroy, et al.
Publicado: (2020) -
Identifying Reliable Diagnostic/Predictive Biomarkers for Rheumatoid
Arthritis
por: Shervington, Leroy, et al.
Publicado: (2018) -
Can CYP1A1 siRNA be an effective treatment for lung cancer?
por: Mohammed, Kulthum, et al.
Publicado: (2008)